Abstract | In this Opinion article, we discuss the function of tissues as a crucial checkpoint for the regulation of effector T cell responses, and the notion that interleukin-15 (IL-15) functions as a danger molecule that communicates to the immune system that the tissue is under attack and poises it to mediate tissue destruction. More specifically, we propose that expression of IL-15 in tissues promotes T helper 1 cell-mediated immunity and provides co-stimulatory signals to effector cytotoxic T cells to exert their effector functions and drive tissue destruction. Therefore, we think that IL-15 contributes to tissue protection by promoting the elimination of infected cells but that when its expression is chronically dysregulated, it can promote the development of complex T cell-mediated disorders associated with tissue destruction, such as coeliac disease and type 1 diabetes. PERSPECTIVES NATURE REVIEWS | IMMUNOLOGY VOLUME 15 | DECEMBER 2015 | 771
The integrity of our tissues is regularly challenged by intracellular infection, in particular by viruses. In response, T helper 1 (T H 1) cell-mediated immunity, which is characterized by the production of interferon-γ (IFNγ) by T cells and a concomitant increase in the number of tissue-resident cytotoxic T cells, is thought to have a key role in tissue protection by promoting the elimination of infected cells [1] [2] [3] . However, concurrent T H 1 cell-mediated immunity and cytotoxic T cell responses are also associated with autoimmunity and tissue destruction [4] [5] [6] . Thus, how tissues control the initiation of T H 1 cell responses and regulate cytotoxic T cells is key to maintaining their integrity.
Interleukin-15 (IL-15) is a member of the four α-helix bundle family of cytokines that includes IL-2, IL-4, IL-7, IL-9 and IL-21. IL-15 shares the common cytokine receptor γ-chain (γc; also known as CD132) of its heterodimeric receptor with the receptors for IL-2, IL-7, IL-4, IL-9 and IL-21, and it shares the β-chain (IL-2/IL-15Rβ; also known as CD122) with the receptor for IL-2 (REFS 7, 8) . IL-15 functions mainly in a cell contact-dependent manner through the trans-presentation of membrane-bound IL-15-IL-15Rα (IL-15 receptor α-subunit) complexes to responding cells that express IL-2/IL-15Rβ-γc 8 . Signalling by cis-presentation or through soluble complexes of IL-15-IL-15Rα 9-11 also contributes, but to a lesser extent, to IL-15-induced responses. By contrast, IL-2, which also signals through IL-2/IL-15Rβ-γc, is mainly produced as a soluble factor by activated T cells 12 (FIG. 1a) and, unlike IL-15, transpresentation by the α-chain of the IL-2 receptor may be only a minor mechanism for IL-2-induced signalling 13 . IL-15 receptor signalling induces JAK1 (Janus kinase 1)-STAT3 (signal transducer and activator of transcription 3) and JAK3-STAT5 activation via the β-chain and γc, respectively 14 . IL-15 is notable among cytokines for being produced by a wide range of cells 14 , including non-myeloid cells such as epithelial and stromal cells, antigen-presenting cells and other myeloid cells such as mastocytes, and B cells and T cells of the adaptive immune system. Furthermore, IL-15 can be induced in response to innate microbial triggers 15, 16 and under conditions of sterile inflammation, reflecting the presence of ongoing cellular distress 17, 18 . Notably, most -if not allorgan-specific autoimmune disorders are associated with IL-15 over expression in the affected tissue [19] [20] [21] [22] [23] [24] [25] [26] , whereas the opposite holds true for the related cytokine IL-2, deficiency of which leads to autoimmunity 27, 28 . The absence of IL-15 in solid tumours is associated with defective lymphocyte activation in the tumour environment and decreased patient survival, which further supports a role for IL-15 in tissue immunity and destruction 29 . Considerable effort has focused on deciphering the role of IL-15 expressed by myeloid cells in the survival and proliferative expansion of natural killer (NK) cells, memory CD8
+ T cells and innate-like intestinal intraepithelial lymphocytes (IELs) 7, 8, 30 (BOX 1). However, the role of IL-15 expressed by non-haematopoietic and haematopoietic tissue-resident cells in the regulation of tissue effector T cell responses and tissue immunity in general is less well recognized. In this Opinion article, we suggest that tissues constitute a crucial checkpoint for the initiation and execution of destructive T cell responses and that IL-15 should thus be recognized as a master regulatory cytokine with regard to tissue immunity. More specifically, we propose that IL-15 is a cytokine that communicates the health status of the tissue to the immune system and has a key role in promoting immune responses that drive tissue destruction through its effects on dendritic cells (DCs) and tissue-resident effector cytotoxic T lymphocytes (CTLs). Finally, we discuss our belief that IL-2 cannot fulfil the same role as IL-15 in tissue immunity and the possible mechanisms that underlie the postulated opposing roles of IL-15 and IL-2 in tissue immunopathology.
Tissue-specific regulation of CTL responses
It has long been thought that the nature of the infectious agent and the innate pathways activated in DCs in response to infection determine which type of immune response (for example, a T H 1, T H 2, T H 17 or regulatory T (T Reg ) cell response) is generated, based on the level of co-stimulatory molecules [32] [33] [34] . In the gut, T H 17 cell responses and peripherally derived T Reg cell responses are promoted to enable the maintenance of intestinal immune homeostasis through the production of secretory IgA and antimicrobial peptides 35 , while still allowing for protective immune responses against pathogens. Although the cellular and molecular The main mechanism by which IL-15 interacts with its receptor in vivo is trans-presentation. IL-15 is assembled as an IL-15-IL-15 receptor α-subunit (IL-15Rα) complex intracellularly in the endoplasmic reticulum (ER), then shuttled to the cell surface and presented by distressed cells in trans to responder cells expressing a heterodimer of the IL-2/IL-15 receptor β-chain (IL-2/IL-15Rβ) and the common cytokine receptor γ-chain (γc). This receptor is constitutively expressed by effector and memory T cells, as well as by natural killer (NK) cells. Unlike IL-15, IL-2 is mainly secreted as a soluble factor by T cells in response to co-stimulation. IL-2 can bind the IL-2/IL-15Rβ-γc receptor with low affinity and interacts with high affinity in an autocrine manner with the trimeric receptor IL-2Rα-IL-2/IL-15Rβ-γc. This trimeric receptor is only transiently expressed on all activated T cells and NK cells. b | Regulation of naive versus effector cytotoxic T lymphocytes (CTLs). Naive or memory CD8 + T cells require, in addition to T cell receptor (TCR) signals (signal 1), co-stimulation (signal 2) provided by CD28 and CD40 ligand (CD40L) -which recognize B7 and CD40, respectively, expressed by dendritic cells -to become activated and undergo differentiation. In the absence of co-stimulation, very little IL-2 is produced by T cells, and cells that receive a TCR signal die or become anergic. IL-2, which is induced in response to signal 2, promotes T cell proliferation and prevents anergy 159 , and it therefore functions as a co-signal. By contrast, tissue-resident effector memory CD8 + T cells classically do not express CD28 and do not require signal 2 for survival. Furthermore, tissue cells do not express B7. However, we propose that a different form of co-stimulation is required for tissue effector CTLs to exert their effector function: signal 2 and co-signal 2 are provided by activating NK receptors recognizing non-classical MHC class I molecules and by IL-15, respectively, that are induced on tissue cells under conditions of stress and infection.
mechanisms underlying the role of tissues in directing T cell differentiation are still being uncovered, known examples have been linked to the functional properties of tissue DCs imparted by the tissue environment. For example, intestinal DCs, which are in an environment rich in retinoic acid, transforming growth factor-β (TGFβ) and IL-6, tend to induce gut-homing receptors on T cells [36] [37] [38] and to promote T Reg cell [39] [40] [41] and T H 17 cell 35, 39, 42 responses. Furthermore, oral but not systemic infection with the pathogen Yersinia enterocolitica triggers the selective induction of T H 17 cell responses instead of T H 1 cell responses through engagement of Toll-like receptor 1 (TLR1) in the presence of TGFβ and retinoic acid 43 . However, although the role of the tissue environment in guiding the early differentiation of T cells is now well recognized, the role of the tissue in controlling the activation status of existing effector T cells -which encompass both tissue-resident effector memory T cells (T RM cells) and recently differentiated effector T cells that have emigrated from lymph nodes 44, 45 -is less well understood. Effector CTLs contain granules that are armed with cytolytic molecules (such as granzyme and perforin) and pro-inflammatory molecules (such as IFNγ). A prototype of T RM cells are IELs, which express CD69 and CD103 (also known as integrin αE), are located between epithelial cells in the intestine and have an important role in immune protection against pathogens 17 . Such tissue-resident effector memory CTLs must provide rapid protection against infection while preventing indiscriminate tissue destruction. Classical immunology textbooks teach us that whereas naive T cells and central memory T cells require co-stimulation (also known as signal 2) in addition to T cell receptor (TCR) stimu lation (signal 1) for their activation (FIG. 1b) , effector T cells require only signal 1 to mediate their effector function. We propose that this notion is only partially correct because although effector CTLs do have the potential to induce cytolysis and produce cytokines in response to TCR stimulation in the absence of costimulation, their activity in these circumstances is largely suboptimal as shown by the very high levels of TCR stimulation that are required in vitro and the low levels of cytolysis and cytokines produced [46] [47] [48] . We therefore suggest that the tissue environment functions as a second checkpoint for effector CTL activation but that this role for the tissue has frequently been overlooked because most studies are not designed to address it. In our view, the best controlled in vivo experiment to address this issue showed that forced migration of effector CTLs in a healthy tissue that expressed the cognate antigen was not sufficient to induce tissue destruction -and, more specifically, diabetes -using a TCR-and β-islettransgenic mouse model 49 . Moreover, there are several examples of mouse models in which the induction of an inflammatory adaptive immune response specific for dietary antigens is insufficient to cause tissue damage when it takes place in an intestine where epithelial cells are originally healthy [50] [51] [52] [53] . (FIG. 1b) .
Comparing roles of IL-2 and IL-15 in vivo
The contrasting associations of IL-15 overexpression and IL-2 deficiency with autoimmunity 27, 28 , which have led to the development of therapies for autoimmune disorders based on selectively blocking IL-15 signalling 18 but on providing low doses of IL-2 (REF. 56 ), suggest that even though IL-2 and IL-15 signal through a common receptor and share some important biological functions 8, 12 , they have distinct roles in vivo. We first present evidence suggesting that there are key similarities between IL-2 and IL-15 biology, before discussing in greater depth the underlying mechanisms that may explain their apparent opposing in vivo roles in autoimmunity.
Similar functions of IL-2 and IL-15 include stimulating the generation, proliferation and activation of NK cells, promoting the proliferation of activated T cells and facilitating the induction of CTLs, as well as inducing the proliferation of, and immunoglobulin synthesis by, pre-activated B cells 8 . . IL-15 receptor signalling contributes to cell proliferation and survival through the phosphorylation and activation of Janus kinase 1 (JAK1) and JAK3, which subsequently recruit and phosphorylate signal transducer and activator of transcription 5 (STAT5) and STAT3 (REF. 8 ). The STAT proteins dissociate from the IL-15 receptor and translocate to the nucleus, where they promote transcription of the gene encoding the anti-apoptotic factor BCL-2 and of the proto-oncogenes MYC, FOS and JUN
14
. IL-15 can also trigger the RAS-RAF-MEK-mitogen-activated protein kinase (MAPK) and the phosphoinositide 3-kinase (PI3K)-AKT signalling pathways, which induce mitogenic signals and BCL-2-and BCL-Xl-mediated anti-apoptotic signals, and can limit the production of the pro-apoptotic proteins BIM (also known as BCL-2L11) and PUMA (also known as BBC3) 14 .
In addition, IL-15 induces iNKT cell and NK cell activation and increases the cytotoxicity of NK cells by enhancing the production of perforin and granzymes A and B . IL-15 supports the survival of unconventional intraepithelial lymphocytes through the activation of JAK-STAT, PI3K-AKT and ERK signalling pathways that lead to the upregulation of BCL-2 and MCL1 expression 14 .
However, strikingly, IL-2-deficient mice develop autoimmune and inflammatory disorders, whereas IL-15-deficient mice do not. Conversely, IL-15 overexpression has been reported in numerous organ-specific autoimmune disorders [19] [20] [21] [22] [23] [24] [25] [26] , whereas to our knowledge there are no reports suggesting a link between IL-2 overexpression and autoimmunity in humans. Furthermore, IL-15-deficient mice have a reduction in the number of NK cells, central memory CD8 + T cells and resident IELs 58 , whereas IL-2-deficient mice develop major hyperlymphoproliferative disorders 27, 28 . These in vivo differences suggest that, although IL-15 and IL-2 exert some common in vivo functions, they also have key distinct functions, as illustrated by the following observations. Although IL-15 was reported to enhance the proliferative expansion of forkhead box P3 (FOXP3) + T Reg cells [59] [60] [61] [62] [63] and to have a role in the development of CD25
, the development of CD25 +
FOXP3
+ T Reg cells is acknowledged to be strictly IL-2 dependent, and IL-2 deficiency is overall associated with a major defect in the homeostatic maintenance of T Reg cells 62, [64] [65] [66] . Furthermore, IL-15 was shown to block the differentiation of peripherally derived T Reg cells, especially in the presence of retinoic acid 51 . Finally, IL-2 promotes the elimination of potentially harmful self-reactive T cells through activationinduced cell death (AICD) 67 , whereas IL-15 is an anti-apoptotic factor in several systems and inhibits AICD 68, 69 . The opposing roles of IL-15 and IL-2 in vivo in terms of AICD are in particular illustrated by a report showing that blocking IL-2 enhances the rate of appearance of dividing CD8 + memory T cells, whereas the absence of IL-2/IL-15Rβ decreases it 70 .
To explain the apparent paradox that IL-2 and IL-15 have distinct roles in vivo yet they signal through a common receptor, investigators in the field have relied on the explanation that IL-2 mainly functions as a soluble factor, whereas IL-15 mainly functions in a cell contact-dependent manner and hence induces signalling in the presence of other co-stimulatory signals provided by the cell trans-presenting IL-15 (REF. 8 ). The main mechanisms by which IL-2 and IL-15 interact with their receptors in vivo are cis-presentation and trans-presentation, respectively (FIG. 1a) , although IL-15 signalling by cis-presentation or through soluble complexes of IL-15Rα-IL-15 (REFS 9-11) and IL-2 signalling by trans-presentation 13 have also been described.
Ultimately, we propose that, in addition to the fact that IL-15, but not IL-2, mainly functions in a cell contact-dependent manner, two crucial differences drive the apparent paradoxical opposing roles of IL-15 and IL-2 in tissue immunopathology. First, IL-2 is typically not produced by antigen-presenting cells or non-haematopoietic cells such as epithelial or stromal cells, and thus it cannot function in a similar manner to IL-15 as a first messenger relaying tissue distress. Second, because IL-2 is secreted transiently and at low levels by tissue-resident effector CTLs 45 , and the produced IL-2 is rapidly consumed by the activated effector T cells and T Reg cells residing in the tissue 12 , we suggest that IL-2 fails to reach sufficient levels in tissues to allow for signalling through the constitutively expressed dimeric IL-2/IL-15Rβ-γc receptor that is shared with IL-15. Consequently, IL-2-mediated signalling by effector T cells in these environments would mainly, if not selectively, take place through the high-affinity trimeric IL-2Rα-IL-2/IL-15Rβ-γc receptor, which is upregulated only in response to TCR signalling. This is in contrast to IL-15, which achieves much higher concentration levels locally because it is trans-presented by the distressed cell to the responder cells 71, 72 and which has the ability to signal selectively through the dimeric receptor because of its tenfold higher affinity than IL-2 for this receptor 57 . If correct, IL-2 and IL-15 would thus signal in T cells that have different activation statuses. Furthermore, the presence or absence of IL-2Rα (also known as CD25) in combination with the different affinity of the two cytokines for their receptors would lead to differences in the physical engagement and signalling of the IL-2/IL-15Rβ chain and γc. This may explain why, although IL-2 and IL-15 regulate a very large set of common genes (that is, 4,284 genes) in peripheral blood CD8 + T cells in vitro, there are 406 and 492 genes that are uniquely regulated by IL-2 and IL-15, respectively 57 , suggesting that the two cytokines also have unique transcriptional properties. This difference might be even more pronounced if studies were carried out on peripheral blood effector CTLs and cytotoxic T RM cells, rather than on global peripheral blood CD8 + T cells, which mainly include central memory and naive T cells.
Future functional and transcriptional profiling studies that compare the effects of different concentrations of IL-2 and IL-15 in resting and TCR-activated memory T cells and T RM cells in the absence or presence of a blocking IL-2Rα-specific antibody will help to further dissect the mechanisms underlying the differential roles of IL-2 and IL-15 in vivo. Similar studies carried out with different DC and innate lymphocyte subsets would also help to delineate the functional impact of these cytokines on tissue DCs and innate lymphocytes. Finally, when analysing the roles of IL-15 and IL-2 in vivo, it is important to take into account where these cytokines are actually expressed and can signal to responder cells under physiopathological conditions. This is illustrated, for example, by the observation that whereas IL-2 and IL-15 can both prevent FOXP3 + T Reg cells from exerting their suppressive functions on effector T cells in vitro 73, 74 , IL-15 but not IL-2 was shown to be present in the joint fluid of patients with juvenile arthritis in vivo, and therefore it can be suggested that IL-15 and not IL-2 is responsible for the T Reg cellinhibitory effect in this case 74 . Furthermore, there is some evidence that IL-15 overexpression in the intestinal epithelium 68 , but not in the lamina propria 51, 55 , promotes the acquisition of activating NK receptors by IELs, and IL-15 (but not IL-2) was reported to be expressed by intestinal epithelial cells 55, 75, 76 .
Role of IL-15 in tissue immunity
Where IL-15 is upregulated and in which cell type it signals have a defining impact on its role in tissue immunity. Here, we discuss in detail the regulation of IL-15 and its immuno pathological effects on DCs and 
Latent autoimmune diabetes in adults
(LADA). A disorder characterized by the presence of diabetes-associated autoantibodies and islet-reactive T cells in the absence of β-cell destruction and overt diabetes.
Lymphokine-activated killer activity
(LAK activity). The ability of T cells to lyse target cells in the absence of specific antigenic stimuli and MHC restriction. LAK cells can be generated in vitro in the presence of interleukin-15 (IL-15) or high concentrations of IL-2.
Potential coeliac disease
A form of coeliac disease defined by the presence of transglutaminase-and gluten-specific antibodies and compatible HLA molecules in the absence of villous atrophy. 83, 84 , endothelial cells 78 , bone marrow and lymph node stromal cells 78, 85 , and tissue cells such as fibroblasts 86 , intestinal and respiratory epithelial cells 75, 76, [87] [88] [89] , hair follicles 90 and keratinocytes 91 . Bacterial and viral infections associated with innate signals such as type I IFN, double-stranded RNA and TLR signalling through MYD88 have been reported to induce IL-15 upregulation 15, 16 . Intriguingly, however, IL-15 has also been reported to be induced in tissues under conditions of sterile inflammation, such as in autoimmune disorders [19] [20] [21] [22] [23] [24] [25] [26] 92 , coeliac disease 75, 76, 93 , inflammatory bowel disease [94] [95] [96] , alopecia areata 90 and sarcoidosis 97 , although the mechanisms underlying these observations remain poorly understood. Key transcription factors that are induced under inflammatory conditions and that regulate IL15 transcription are nuclear factor-κB (NF-κB; in particular p50) and IFN regulatory factor 1 (IRF1), the binding motifs for which are found in the promoter region of IL15 (REF. 98 ). Whether other factors associated with tissue stress, such as oxidative stress, DNA damage, endoplasmic reticulum stress or metabolic alterations, are associated with IL-15 upregulation remains to be determined. Interestingly, many of the susceptibility genes for coeliac disease and, more generally, for autoimmune and inflammatory disorders have a functional connection with IL-15, which suggests that IL-15 dysregulation in these diseases may result from alterations of this network. Whatever the mechanisms underlying IL-15 overexpression, the fact that it functions in a cell contact-dependent manner has major implications because the location of IL-15 upregulation will determine its biological effect.
Tissue-resident effector memory T cells (T RM cells
Effect on DCs and the development of T H 1 cells. Because of the importance of T H 1 cell-mediated immunity in the protection against intracellular microorganisms and as a pathological mediator of autoimmunity, the factors that are required to promote DC production of IL-12p70, a major cytokine involved in T H 1 cell differentiation, are of major interest. Importantly, the lack of IL-2/IL-15Rβ expression by DCs has been shown to affect IL-12 production and signalling in DCs ex vivo and in vitro 99 . In addition, IL-15-deficient mice but not IL-2-deficient mice mimic this defect in IL-12 production, which indicates a crucial role for IL-15-induced signalling in DCs for the induction of T H 1 cell-mediated immunity through IL-12 production 99 (FIG. 2) .
Furthermore, it has been demonstrated that IL-15 promotes T H 1 cell-mediated immune responses in the intestinal environment by synergizing with retinoic acid to induce the differentiation of inflammatory DCs in a JUN N-terminal kinase 2 (JNK2; also known as MAPK9)-dependent manner 51 . Finally, the acquisition of an inflammatory phenotype by DCs upon stimulation with IL-15 is also made evident by the increased ability of IL-15-stimulated DCs to secrete IFNγ, to stimulate the proliferation of antigen-specific CD8 + T cells and to activate NK cells 81, 100 . This ability of IL-15 to promote DC-mediated T H 1 cell responses led to efforts to use IL-15-treated DCs as a potential vaccine for cancer therapy 101, 102 . In addition, IL-15 was shown to promote IL-23 secretion by intestinal DCs and T H 17 cell differentiation in the presence of IL-6 (REFS 51,103). Thus, a role for IL-15 has also been uncovered in diseases such as psoriasis 22, 23 and auto immune encephalomyelitis 103 , in which IL-17 is thought to have a more important role in immunopathology than IFNγ.
Licensing of effector CTLs to mediate tissue destruction. The focus of this Opinion is not to discuss the largely reviewed effects of IL-15 on the homeostasis of NK cells, invariant NKT cells and CD8
+ T cells 8, 14, 104 but to address its role in the regulation of effector CTL responses in tissues. Here, we discuss the ability of IL-15 to reduce the TCR activation threshold of CTLs by providing co-stimulation, to promote lymphokineactivated killer activity (LAK activity) in CTLs (defined as the ability of a cytokine to enable a CTL to mediate cytolysis independently of the TCR and in the absence of MHC restriction) and to render CTLs resistant to T Reg cells. The ability of IL-15 to promote the cytolytic functions of effector CTLs and their production of IFNγ was first suggested by studies looking at the effect of IL-15 on IELs, which are a prototypical example of cytotoxic T RM cells 105, 106 . Follow-up studies showed that IL-15 increased TCR-mediated cyto lysis in IELs 48 . This is made possible because, similarly to CD28, IL-15 can activate phospho inositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) signalling pathways [107] [108] [109] and thereby functions as a co-stimulatory molecule for the TCR (FIG. 3) . The ability of IL-15 to reduce the TCR activation threshold for effector CTLs may provide a mechanistic basis to explain the ability of CD8 + T cells to recognize self-antigens in vitro in a TCR-dependent process 46 and to mediate in vivo the destruction of solid tumours lacking expression of cognate antigen in a TCR-dependent manner 47 when IL-15 is present.
In addition to directly functioning as a co-stimulatory signalling molecule for the TCR, IL-15 promotes the expression of the NK receptors NKG2D (natural killer group 2, member D) 48, 107, 110 and CD94 (REFS 75, 111) , which themselves can function as co-stimulatory receptors for the TCR in effector CTLs 5 . Importantly, human tissue cells can upregulate expression of the non-classical MHC class I or class I-like molecules HLA-E and MICA (MHC class I polypeptide-related sequence A) under conditions of stress or activation, which are ligands for CD94-NKG2 receptor family and NKG2D receptors, respectively 107, 112, 113 . NKG2D, like CD28, associates with the adaptor molecule DNAX-activation protein 10 (DAP10), which contains a PI3K motif 114, 115 . Shortly after its discovery, NKG2D was shown to co-stimulate the TCR in virus-specific T cells 116 and in cytolytic IELs 48 . Furthermore, NKG2D was proposed to have a key role in the regulation of tissueresident effector T cells 48 . This is particularly relevant for human physiopathology because cytotoxic T RM cells generally lack expression of the co-stimulatory receptor CD28 (REFS 48, 117) , and human tissue cells lack expression of its B7 ligands (also known as CD80 and CD86).
Finally, IL-15 has been shown to increase the expression of cytotoxic effector molecules such as TNF-related apoptosis-inducing ligand (TRAIL; also known as TNFSF10) and perforin 118 , and to endow effector CTLs with LAK activity -in other words, to enable NKG2D-DAP10 signals to mediate TCRindependent cytolysis 48, 107 . This property of IL-15 is linked to its ability to function as a co-stimulatory molecule for the NKG2D-mediated cytolysis signalling pathway by synergizing with NKG2D to promote the activation of PI3K, JNK, extracellular signal-regulated kinase (ERK) and cytosolic phospholipase A2 (cPLA2) 107, 109, 119 (FIG. 3) . By promoting the activation of cPLA2, IL-15 also induces the release of arachidonic acid to promote tissue inflammation together with cell lysis 48, 107, 109 . Whether and how STAT3 and STAT5 (which are downstream of the IL-15 receptor) are involved in the regulation of NK receptor expression and function in CTLs remain to be determined.
In summary, we propose that IL-15 has the ability to enable effector CTLs to kill damaged tissue cells based on the recognition of stress and inflammatory signals rather than a cognate antigen through two distinct, but not mutually exclusive, mechanisms:
by decreasing the TCR activation threshold of effector CTLs and by inducing TCRindependent LAK activity in CTLs (FIG. 2) . In the absence of specific antigen recognition, the targeting of tissue cells by effector CTLs remains highly specific as it involves receptor-ligand interactions that direct CTLs exclusively against cells that upregulate expression of IL-15 and non-classical MHC class I or class I-like molecules. Furthermore, IL-15 confers such properties to effector but not central memory CTLs -in other words, only to T cells that have undergone recent activation through their TCR, which further helps to contain and restrict the potent effects of IL-15.
Rendering CTLs resistant to T Reg cells.
Following the discovery that T Reg cells have an important role in preventing autoimmunity 120 , it was surprising to find that the number of T Reg cells is increased in tissues of patients with autoimmune diseases 121 . In particular, studies have shown that there is an increase in the number of CD4 + CD25 hi T cells that have suppressive functions and express cytotoxic T lymphocyte-associated antigen 4 (CTLA4), glucocorticoidinduced TNFR-related protein (GITR; also known as TNFRSF18) and OX40 (also known as TNFRSF4) -the classical T Reg cell phenotype -in patients with rheumatoid arthritis 122, 123 and inflammatory bowel disease 124, 125 . This suggests that, at least in these cases, the increase in the number of FOXP3 + T cells that is observed in humans is probably not due to a failure to discriminate between effector and regulatory T cells. This led to further analysis of the ability of T Reg cells to exert their regulatory functions and to the discovery that several cytokines of the γc family, including IL-15, IL-7 and IL-2, could prevent T Reg cells from exerting their suppressive effect on effector CD4 + T cells in vitro. However, only IL-15 and IL-7 were present in the synovial fluid, suggesting that these cytokines, but not IL-2, limit the suppressive effect of T Reg cells in patients with juvenile arthritis 74 (FIG. 2) . These direct effects of IL-15 on T Reg cells and their suppressive functions, together with the ability of IL-15 to inhibit IL-2-induced AICD of effector lymphocytes 126 , underline the ability of IL-15 to interfere with immune tolerance. Nature Reviews | Immunology Hence IL-15, a cytokine that is induced in distressed tissues, profoundly changes the functional phenotype of differentiated immune cells, favouring the development of T H 1 cell responses, decreasing the TCR activation threshold of effector CTLs and endowing them with LAK activity, and rendering effector T cells insensitive to the suppressive effects of T Reg cells. All of these properties are tailored towards favouring the destruction of tissue cells (FIG. 2) , which may be beneficial in the context of intracellular infection but is deleterious in the context of autoimmunity.
Role of IL-15 in health and disease
Taking into account the proposed role of IL-15 in the tissue-specific regulation of effector T cell responses, here we discuss its role in protection against infection and in autoimmunity. Conversely, we suggest that the lack of IL-15 and stress signals in solid tumours may have a crucial role in the inability of CTLs to eliminate such tumours (FIG. 4) .
Protection of tissues against pathogens.
Protection against intracellular microorganisms is primarily mediated by CTLmediated destruction of infected cells.
A key immune evasion strategy used by intracellular pathogens is to downregulate MHC class I expression by infected cells to prevent TCR-mediated recognition by CTLs 127 . However, the host has evolved mechanisms to counteract pathogen immune evasion and ensure protective immunity that involve upregulation of the expression of IL-15 and non-classical MHC molecules. Intracellular pathogens such as mycobacteria 128 , listeria 129 , Cryptosporidium parvum 130 and a wide range of viruses 89, [131] [132] [133] have been reported to induce IL-15 expression, probably downstream of the activation . Both IL-15 and NKG2D can hence co-stimulate T cell receptor (TCR) signalling and enhance TCR-mediated effector functions and cell survival. As a result, IL-15-induced signalling in cytotoxic T lymphocytes (CTLs) substantially reduces the TCR activation threshold, enabling CTLs to recognize low-avidity antigens and acquire the potential for autoreactivity. Furthermore, by functioning as a co-stimulatory molecule for the NKG2D-mediated signalling pathway, IL-15 enables NKG2D to mediate direct cytolysis (that is, lymphokine-activated killer (LAK) activity), independently from signalling through the TCR. In addition, IL-15 activates the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway, leading to the phosphorylation of STAT3 and STAT5 and the formation of STAT dimers that traffic to the nucleus for transcriptional activation. How the JAK-STAT pathway intersects with TCR and NKG2D signalling remains to be determined. Arrows and words in bold highlight pathways and molecules activated by IL-15. γc, common cytokine receptor γ-chain; IL-2/IL-15Rβ, IL-2/IL-15 receptor β-subunit; IL-15Rα, IL-15 receptor α-subunit; NFAT, nuclear factor of activated T cells; NF-κB, nuclear factor-κB; NK, natural killer. 89, 130, 134 . Of note, induction of these non-classical MHC class I molecules is not directly mediated by IL-15 (REF. 135 ) and occurs in response to heat shock factor 1, hyper proliferation and DNA damage 136, 137 . The ability of IL-15 to function as a costimulatory signalling molecule for the TCR (see earlier) and to induce the expression 130, 134, [138] [139] [140] . Interestingly, viruses have developed several strategies to prevent the expression of NK receptor ligands on the surface of infected cells 141 , which indicates that this is an effective host strategy and must be countered by viruses for them to survive.
In summary, in response to an infection with intracellular pathogens, IL-15 activates key immune cell types and effector functions that are crucial for the destruction of infected cells. Furthermore, because IL-15 functions in a cell contact-dependent manner and the upregulation of its expression ends with the clearance of the pathogen, CTLs are only activated in a transient manner and specifically target infected cells. This mechanism provides protection for tissues against pathogens while avoiding indiscriminate tissue destruction.
Autoimmune responses. The same properties that we believe enable IL-15 to mediate protection against pathogens are probably responsible for its role in the pathogenesis of organ-specific autoimmune disorders in which its expression is dysregulated. IL-15 expression is stringently regulated at the levels of transcription, translation and intracellular trafficking to avoid excessive protein production and secretion 98 
. However, for unknown reasons, IL-15 has been found to be constitutively upregulated in tissue cells that are targeted by a wide variety of autoimmune processes, such as rheumatoid arthritis 19, 20 , multiple sclerosis 21, 142 , psoriatic arthritis or psoriasis 22, 23 145 , increases the cytotoxic properties of CD8 + T cells from patients with multiple sclerosis 84 and is associated with NKG2D upregulation in patients with alopecia areata 90 . Inhibition of JAK1 and JAK2 in patients with alopecia areata who overexpress IL-15 in their hair follicles leads to a near-complete restoration of hair growth 90 , which suggests that IL-15 has a pathogenic role, although it cannot be excluded that JAK inhibition could affect signalling induced by other cytokines such as IL-2. Other strong evidence in support of a role for IL-15 in tissue destruction in the context of autoimmune disorders is provided by observations in patients with LADA or potential coeliac disease who maintain normal tissue integrity despite having developed an adaptive T cell response specific for β-islet cells or gluten, respectively (FIG. 5) . Indeed, IL-15 is upregulated in the serum and β-islet cells of patients with type 1 diabetes but not with LADA 26, 146 . Similarly, patients with active coeliac disease, but not potential coeliac disease, overexpress IL-15 in their epithelium 55 . Moreover, and in support of a primary role for IL-15 in mediating tissue destruction, we found that a subset of family members of patients with active coeliac disease had normal intestinal architecture and no signs of adaptive anti-gluten immunity but had epithelial cells expressing high levels of IL-15. Strikingly, IL-15 overexpression was absent in patients with potential coeliac disease. In accordance with IL-15 having a role in the licensing of cytotoxic T RM cells to kill, only IELs from family members with high levels of IL-15 expression had upregulated expression of NKG2D and activating CD94 NK receptors 55 . The absence of villous atrophy in these individuals correlated with the presence of IELs with high levels of inhibitory CD94-NKG2A receptors 55 and of epithelial cells that failed to upregulate expression of MICA (B.J., unpublished observation). These observations in humans are consistent with reports in transgenic mouse models showing that antigen-specific CTLs fail to mediate tissue destruction despite the presence of cognate antigens when the tissue is healthy and hence fails to provide stress signals to the immune system 49 .
Box 2 | Post-transcriptional regulation of IL-15
To tightly control the function of this potent pro-inflammatory cytokine, interleukin-15 (IL-15) expression is tightly regulated at several levels to limit its translation and secretion. First, IL-15-mediated signalling requires that the IL-15 receptor α-subunit (IL-15Rα) is expressed on the cell surface through a mechanism known as trans-presentation (FIG. 1b) . More specifically, IL-15 is transported through the Golgi apparatus to the cell surface as a complex bound to IL-15Rα. The complex is then presented by membrane-bound IL-15Rα in trans to responder cells expressing the IL-2/IL-15 receptor β-chain (IL-2/IL-15Rβ) and the common cytokine receptor γ-chain (γc) of the IL-15 receptor 8 . In addition, IL-15 associated with IL-15Rα can be cleaved into soluble complexes to mediate IL-15 responses 9, 10 . Second, IL-15 expression is regulated post-transcriptionally by several distinct mechanisms. Unlike the 5ʹ untranslated regions (UTRs) of effectively translated mRNAs, which are short and devoid of AUGs, the 5ʹ UTR of IL15 is long and contains many AUG sites upstream of the initiation AUG, thus restricting the translation of IL15 mRNA 98 . The presence of a carboxy-terminal negative regulatory element in the IL-15 mature protein also contributes to control translation 98 . Finally, IL-15 exists as two isoforms generated by alternative splicing. Both produce mature proteins that are associated with alternative signal peptides 98 . The long signal peptide is associated with the secreted soluble form of IL-15, whereas the short signal peptide is associated with a cytoplasmic or nuclear form of IL-15, the intracellular localization of which could be consistent with a role as a transcriptional regulator 98 . Therefore, not only do these signal peptides contribute to the regulation of IL-15 translation, but they also influence the intracellular trafficking of the protein. However, the exact roles of those isoforms are unclear, as is whether their expression and regulation are tissue specific. 155 are cytokines that, similarly to IL-15, are inducibly expressed by nonhaematopoietic epithelial and stromal cells and have the capacity to relay the health status of the tissue to the immune system and modulate the immune response accordingly. Whereas type I IFN and IL-15 drive mostly T H 1 cell-mediated immunity, IL-33 and TSLP promote T H 2 cell-mediated immunity. These cytokines could thus also be considered to be master regulatory cytokines of tissue immunity. Interestingly, IL-15 has been found in all mammals sequenced so far, as well as in many reptiles and birds, which shows that this cytokine has been conserved for more than 250 million years of evolution and indicates that it is likely to have an important role in survival. The role of IL-15 and all of its pleiotropic immunological properties can be summarized in terms of its ability to promote the destruction of infected tissue cells. More generally, we propose that tissue destruction by cytotoxic T RM cells only occurs when tissue cells provide them with a 'kill me' signal. Furthermore, additional cytokines associated with complex immune disorders 156, 157 , such as IL-21, could synergize 
